Canlyniadau Chwilio - Rodrigues, D N

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail gan Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents gan Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G

Cael y testun llawn Cael y testun llawn Cael y testun llawn

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair gan Shenoy, T. R., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D. N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D. Y., de Bono, J., Wu, H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn